Biofrontera Inc. (NASDAQ:BFRI) Sees Significant Growth in Short Interest

Biofrontera Inc. (NASDAQ:BFRI) saw a large increase in short interest in the month of April. As of April 15th, there was short interest totalling 44,000 shares, an increase of 26.4% from the March 31st total of 34,800 shares. Currently, 1.2% of the company’s shares are short sold. Based on an average daily trading volume, of 759,100 shares, the days-to-cover ratio is currently 0.1 days.

Biofrontera Trading Up 6.4 %

NASDAQ:BFRI traded up $0.11 during mid-day trading on Tuesday, hitting $1.84. The company had a trading volume of 36,545 shares, compared to its average volume of 617,590. Biofrontera has a fifty-two week low of $0.61 and a fifty-two week high of $13.42. The business’s fifty day moving average is $1.43 and its two-hundred day moving average is $2.38.

Biofrontera (NASDAQ:BFRI) last announced its earnings results on Friday, March 15th. The company reported ($2.33) EPS for the quarter. The company had revenue of $10.60 million for the quarter. Biofrontera had a negative return on equity of 344.98% and a negative net margin of 59.09%. On average, equities analysts expect that Biofrontera will post -4.01 earnings per share for the current year.

Institutional Investors Weigh In On Biofrontera

A hedge fund recently bought a new stake in Biofrontera stock. Rosalind Advisors Inc. acquired a new position in shares of Biofrontera Inc. (NASDAQ:BFRI) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 504,261 shares of the company’s stock, valued at approximately $777,000. Biofrontera makes up 0.7% of Rosalind Advisors Inc.’s investment portfolio, making the stock its 27th largest holding. Rosalind Advisors Inc. owned 9.91% of Biofrontera at the end of the most recent quarter. 10.08% of the stock is owned by hedge funds and other institutional investors.

Biofrontera Company Profile

Biofrontera Inc, a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection.